CN109311865A - 抗乙肝病毒的吡唑-噁唑烷酮类化合物 - Google Patents

抗乙肝病毒的吡唑-噁唑烷酮类化合物 Download PDF

Info

Publication number
CN109311865A
CN109311865A CN201780035186.6A CN201780035186A CN109311865A CN 109311865 A CN109311865 A CN 109311865A CN 201780035186 A CN201780035186 A CN 201780035186A CN 109311865 A CN109311865 A CN 109311865A
Authority
CN
China
Prior art keywords
base
fluorophenyl
pyrazoles
bromophenyl
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780035186.6A
Other languages
English (en)
Other versions
CN109311865B (zh
Inventor
陈焕明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zhimeng Biopharma Inc
Original Assignee
Shanghai Zhimeng Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zhimeng Biopharma Inc filed Critical Shanghai Zhimeng Biopharma Inc
Publication of CN109311865A publication Critical patent/CN109311865A/zh
Application granted granted Critical
Publication of CN109311865B publication Critical patent/CN109311865B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一类具有抗乙肝病毒活性的吡唑‑噁唑烷酮化合物，其具有式(I)的结构，其中各变量如本文所定义。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201780035186.6A 2016-04-06 2017-04-06 抗乙肝病毒的吡唑-噁唑烷酮类化合物 Active CN109311865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016102104220 2016-04-06
CN201610210422 2016-04-06
PCT/CN2017/079552 WO2017173999A1 (zh) 2016-04-06 2017-04-06 抗乙肝病毒的吡唑-噁唑烷酮类化合物

Publications (2)

Publication Number Publication Date
CN109311865A true CN109311865A (zh) 2019-02-05
CN109311865B CN109311865B (zh) 2021-08-31

Family

ID=60000897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780035186.6A Active CN109311865B (zh) 2016-04-06 2017-04-06 抗乙肝病毒的吡唑-噁唑烷酮类化合物

Country Status (15)

Country Link
US (1) US10519145B2 (zh)
EP (1) EP3441389B1 (zh)
JP (1) JP6581745B2 (zh)
KR (1) KR102083818B1 (zh)
CN (1) CN109311865B (zh)
CY (1) CY1124671T1 (zh)
DK (1) DK3441389T3 (zh)
ES (1) ES2893208T3 (zh)
HR (1) HRP20211907T1 (zh)
LT (1) LT3441389T (zh)
PL (1) PL3441389T3 (zh)
PT (1) PT3441389T (zh)
RS (1) RS62597B1 (zh)
SI (1) SI3441389T1 (zh)
WO (1) WO2017173999A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685473A (zh) * 2020-12-25 2022-07-01 杭州百新生物医药科技有限公司 5-烷基-2-吡唑-恶唑烷-4-酮类衍生物及其用途
WO2023001298A1 (zh) * 2021-07-23 2023-01-26 上海挚盟医药科技有限公司 一种乙肝病毒核衣壳抑制剂的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013085A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb).
US20220227789A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
EP3962909B1 (en) 2019-04-30 2023-10-04 AiCuris GmbH & Co. KG Novel oxalyl piperazines active against the hepatitis b virus (hbv)
EP3962912A1 (en) 2019-04-30 2022-03-09 AiCuris GmbH & Co. KG Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
CN112574188B (zh) * 2019-09-29 2022-05-06 苏州爱科百发生物医药技术有限公司 一种吡唑类化合物及其应用
CN115677680A (zh) * 2021-07-23 2023-02-03 上海挚盟医药科技有限公司 式i化合物的晶型及其制备和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033995A2 (en) * 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
WO2007014023A1 (en) * 2005-07-21 2007-02-01 Valeant Research & Development Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033995A2 (en) * 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
WO2007014023A1 (en) * 2005-07-21 2007-02-01 Valeant Research & Development Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685473A (zh) * 2020-12-25 2022-07-01 杭州百新生物医药科技有限公司 5-烷基-2-吡唑-恶唑烷-4-酮类衍生物及其用途
WO2023001298A1 (zh) * 2021-07-23 2023-01-26 上海挚盟医药科技有限公司 一种乙肝病毒核衣壳抑制剂的制备方法

Also Published As

Publication number Publication date
PT3441389T (pt) 2021-11-11
KR102083818B1 (ko) 2020-03-03
EP3441389A4 (en) 2019-09-04
US20190152963A1 (en) 2019-05-23
EP3441389A1 (en) 2019-02-13
SI3441389T1 (sl) 2022-01-31
PL3441389T3 (pl) 2022-01-24
ES2893208T3 (es) 2022-02-08
JP6581745B2 (ja) 2019-09-25
US10519145B2 (en) 2019-12-31
CN109311865B (zh) 2021-08-31
HRP20211907T1 (hr) 2022-03-18
LT3441389T (lt) 2021-10-11
RS62597B1 (sr) 2021-12-31
DK3441389T3 (da) 2021-11-08
WO2017173999A1 (zh) 2017-10-12
EP3441389B1 (en) 2021-09-08
CY1124671T1 (el) 2022-07-22
KR20180128953A (ko) 2018-12-04
JP2019513830A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
CN109311865A (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
CN108341777A (zh) 异喹啉酮类化合物及其应用
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
TW202043212A (zh) Shp2抑制劑及其應用
CN110092745B (zh) 一种含芳环的化合物及其应用
CN108602811A (zh) Fxr 受体激动剂
CN106459009A (zh) 丙肝病毒抑制剂及其制药用途
US10517870B2 (en) Aryl substituted bicycle heteroaryl compounds
CN103476776B (zh) 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN105566276B (zh) 作为dpp-4抑制剂的苯并六元环衍生物及其应用
TW202035412A (zh) 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法
CN107567452A (zh) 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途
WO2018090862A1 (zh) 二氢嘧啶类化合物及其制备方法和用途
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN114667289A (zh) 杂芳基血浆激肽释放酶抑制剂
CN108689937B (zh) 吲唑类化合物及其在制备ido抑制剂类药物上的用途
CN111630047B (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
CN113329998A (zh) 用于治疗与nlrp活性相关的病症的磺酰亚胺酰胺化合物和组合物
JP7250015B2 (ja) 抗ＨＢＶのテトラヒドロイソキサゾロ［４，３－ｃ］ピリジン類化合物
CN106146533B (zh) 含硫杂环羧酸类衍生物、其制备方法和应用
CN108299420A (zh) 作为选择性雌激素受体下调剂的五环类化合物及其应用
TWI839738B (zh) 含氮雜環化合物、其製備方法及應用
CN115960105A (zh) Kras g12d抑制剂及其在医药上的应用
CN113493453B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN112608315B (zh) 三唑并二氮杂卓类化合物及其制备方法及医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Room A302 and A304, building 1, No. 1976, Gaoke Middle Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai 201210

Applicant after: SHANGHAI ZHIMENG BIOPHARMA Co.,Ltd.

Address before: Room 0285, No. 1025 Canal North Road, Nanqiao Town, Fengxian District, Shanghai, 20149

Applicant before: SHANGHAI ZHIMENG BIOPHARMA Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant